CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc.

1:15-cv-00710

Overview

Case Number 1:15-cv-00710
Filing Date 2015-08-18
Status Terminated
Termination Date 2016-01-25
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Plaintiff

Parties

Defendant

TWi Pharmaceuticals, Inc. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Ave., Suite 200, Wilmington, DE 19801

TWi Pharmaceuticals USA, Inc. Operating Company

Represented By

1 Attorneys Listed

Dominick T. Gattuso

Heyman Enerio Gattuso & Hirzel LLP

Tel: +1 (302) 472-7311
Fax: +1 (302) 472-7301

300 Delaware Ave., Suite 200, Wilmington, DE 19801

Plaintiff

Alkermes Pharma Ireland Limited NPE (University / Research)

Represented By

3 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell

Tel: +1 (302) 658-9200

1201 North Market St., P.O. Box 1347, Wilmington, DE 19899

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell

Tel: +1 (302) 351-9106

1201 North Market St., P.O. Box 1347, Wilmington, DE 19899

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell

Tel: +1 (302) 658-9200

1201 North Market St., P.O. Box 1347, Wilmington, DE 19899

Par Pharmaceutical, Inc. Operating Company

Represented By

5 Attorneys Listed

James L. Higgins

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-5034

1000 North King St., Rodney Square, Wilmington, DE 19801

Karen L. Pascale

Young, Conaway, Stargatt & Taylor LLP

Tel: +1 (302) 571-6600

1000 North King St., Rodney Square, Wilmington, DE 19801

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 3 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (3 found):
U.S. Courts: 3
U.S. District Court 2015-11-11
1:15-cv-01039

Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.

Asserted Patent
Status: DED
U.S. District Court 2015-08-11
1:15-cv-00698

Par Pharmaceutical, Inc. v. TWi Pharmaceuticals, Inc.

U.S. Family Sibling (["US9101540", "US9101549"])
Status: DED
U.S. District Court 2013-06-21
1:13-cv-01114

Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.

U.S. Family Sibling (["US7101576", "US6592903"])
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US9107827
Nanoparticulate megestrol formulations
Filed: 2014-11-07
Issued: 2015-08-18
Active (8.0 yrs remaining)
Expires: 2034-11-07

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Active Threat

Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Docket Entries

(30 total)
Pleading / Complaint

COMPLAINT filed with Jury Demand against TWi Pharmaceuticals USA, Inc., TWi Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1771613.) - filed by Par Pharmaceutical, Inc., Alkermes Pharma Ireland Limited. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(nmb) (Entered: 08/18/2015)

Entry #1 • 2015-08-18
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 08/18/2015)

Entry #2 • 2015-08-18
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: July 21, 2011. Date of Expiration of Patent: April 22, 2024. (nmb) (Entered: 08/18/2015)

Entry #3 • 2015-08-18
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,107,827 B2;. (nmb) (Entered: 08/18/2015)

Entry #4 • 2015-08-18
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Par Pharmaceutical, Inc.. (nmb) (Entered: 08/18/2015)

Entry #5 • 2015-08-18
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc